This paper discusses the advantage of using repeated outcome measurements on subjects in a clinical trial. We choose the number of subjects and the number of repeated outcome measurements to minimize a given cost function so that the clinical trial has power (1-beta) for specified significance level alpha. An example illustrates the results and emphasizes the importance of study design and of critical evaluation of how one measures the study endpoint.